

GLAXOSMITHKLINE PLC  
Form 6-K  
August 14, 2015

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending August 2015

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--

GlaxoSmithKline plc

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibilities or Connected Persons

In accordance with DTR 3.1.4 R(1)(a) and (c) GlaxoSmithKline plc ('GSK') was advised on 14 August 2015 of the following increase in the notional allocation of GSK American Depositary Shares ('ADSs') on 13 August 2015, at a price of \$43.89 per ADS, following the revaluation of the cash element of the notional investment held within the GSK 401K plan:

| Director/PDMR | Number of<br>ADSs |
|---------------|-------------------|
|---------------|-------------------|

|             |    |
|-------------|----|
| Dr M Slaoui | 20 |
|-------------|----|

| Connected person | Number of ADSs |
|------------------|----------------|
|------------------|----------------|

|  |   |
|--|---|
| Dr K Slaoui (connected<br>person of Dr M Slaoui) | 1 |
|--|---|

V A Whyte  
Company Secretary

14 August 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: August 14, 2015

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc